F
Farhad Ravandi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1445
Citations - 44402
Farhad Ravandi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 90, co-authored 1249 publications receiving 34816 citations. Previous affiliations of Farhad Ravandi include Dana Corporation & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian,Xavier Thomas,Anna Dmoszynska,Agnieszka Wierzbowska,Grzegorz Mazur,Jiri Mayer,Jyh Pyng Gau,Wen-Chien Chou,Rena Buckstein,Jaroslav Cermak,Ching Yuan Kuo,Albert Oriol,Farhad Ravandi,Stefan Faderl,Jacques Delaunay,Daniel Lysák,Mark D. Minden,Christopher Arthur +17 more
TL;DR: In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
Journal ArticleDOI
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian,Yasuhiro Oki,Guillermo Garcia-Manero,Xuelin Huang,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Carlos E. Bueso-Ramos,Farhad Ravandi,Zeev Estrov,Alessandra Ferrajoli,William G. Wierda,Jianqin Shan,Jan Davis,Francis J. Giles,Hussain I. Saba,Jean Pierre J. Issa +16 more
TL;DR: It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.
Journal ArticleDOI
Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology
Margaret R. O'Donnell,Martin S. Tallman,Camille N. Abboud,Jessica K. Altman,Frederick R. Appelbaum,Daniel A. Arber,Vijaya Raj Bhatt,Dale L. Bixby,William Blum,Steven Coutre,Marcos de Lima,Amir T. Fathi,Melanie Fiorella,James M. Foran,Steven D. Gore,Aric C. Hall,Patricia Kropf,Jeffrey E. Lancet,Lori J. Maness,Guido Marcucci,Michael Gary Martin,Joseph O. Moore,Rebecca L. Olin,Deniz Peker,Daniel A. Pollyea,Keith W. Pratz,Farhad Ravandi,Paul J. Shami,Richard Stone,Stephen A. Strickland,Eunice S. Wang,Matthew J. Wieduwilt,Kristina M. Gregory,Ndiya Ogba +33 more
TL;DR: This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger and older adult patients.
Journal ArticleDOI
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Guillermo Garcia-Manero,Hagop M. Kantarjian,Blanca Sanchez-Gonzalez,H. Yang,Gary L. Rosner,Srdan Verstovsek,Michael Rytting,William G. Wierda,Farhad Ravandi,Charles Koller,Lianchun Xiao,Stefan Faderl,Zeev Estrov,Jorge E. Cortes,Susan O'Brien,Elihu H. Estey,Carlos E. Bueso-Ramos,Jackie Fiorentino,Elias J. Jabbour,Jean Pierre J. Issa +19 more
TL;DR: This combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks.
Journal ArticleDOI
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Hagop M. Kantarjian,Susan O'Brien,Farhad Ravandi,Jorge E. Cortes,Jianqin Shan,John M. Bennett,Alan F. List,Pierre Fenaux,Guillermo Sanz,Jean Pierre J. Issa,Emil J. Freireich,Guillermo Garcia-Manero +11 more
TL;DR: Issues with the IPSS model are highlighted in relation to the exclusion of many subgroups that now represent a large proportion of patients with myelodysplastic syndrome and its lack of applicability to most patients on investigational programs.